JAN (NYSE:JAN) Stock Rating Upgraded by Jefferies Financial Group

JAN (NYSE:JAN) was upgraded by research analysts at Jefferies Financial Group to a “strong-buy” rating in a research report issued to clients and investors on Tuesday, Zacks reports.

Several other brokerages also recently weighed in on JAN. Royal Bank Of Canada boosted their price objective on shares of JAN from $30.00 to $34.00 and gave the stock an “outperform” rating in a research report on Monday, August 10th. Morgan Stanley lifted their price target on shares of JAN from $28.00 to $31.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 18th. JPMorgan Chase & Co. boosted their price target on shares of JAN from $30.00 to $34.00 and gave the company an “overweight” rating in a research report on Tuesday, August 18th. Scotiabank upped their price objective on shares of JAN from $30.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, September 2nd. Finally, Barclays raised their price objective on JAN from $33.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, August 31st. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, JAN presently has a consensus rating of “Moderate Buy” and an average price target of $32.31.

JAN Trading Down 3.4%

Shares of NYSE JAN opened at $30.52 on Tuesday. The stock’s 50-day simple moving average is $30.48. JAN has a fifty-two week low of $22.76 and a fifty-two week high of $32.83.

JAN (NYSE:JAN) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.18). The company had revenue of $216.46 million during the quarter, compared to analysts’ expectations of $203.32 million. JAN’s quarterly revenue was up 45.4% compared to the same quarter last year. JAN has set its FY 2026 guidance at 0.950-0.980 EPS. Equities analysts forecast that JAN will post 0.97 EPS for the current year.

Institutional Trading of JAN

Large investors have recently bought and sold shares of the business. Engineers Gate Manager LP purchased a new position in JAN during the 2nd quarter worth $15,274,000. Wellington Management Group LLP purchased a new stake in shares of JAN in the second quarter valued at about $8,739,000. WINTON GROUP Ltd purchased a new stake in shares of JAN in the second quarter valued at about $2,985,000. Readystate Asset Management LP acquired a new stake in shares of JAN during the second quarter worth about $1,724,000. Finally, Greenland Capital Management LP purchased a new position in shares of JAN during the second quarter worth about $575,000. Institutional investors and hedge funds own 6.27% of the company’s stock.

Key Headlines Impacting JAN

Here are the key news stories impacting JAN this week:

• Positive Sentiment: Jefferies’ upgrade to “strong buy” provides fresh analyst support for JAN and may attract additional buying from investors who follow rating changes. Zacks analyst upgrade report
• Positive Sentiment: Analysts have an average price target of approximately $31.71, modestly above the reference price of $30.52, suggesting some additional upside in the consensus outlook. JAN receives $31.71 average price target
• Neutral Sentiment: JAN’s latest quarter included revenue of $216.46 million, up 45.4% year over year and above estimates, but earnings per share of $0.05 missed consensus by $0.18. Management’s fiscal 2026 EPS guidance remains $0.95–$0.98, broadly consistent with analyst expectations of $0.97.
• Neutral Sentiment: The shares opened near their 50-day moving average of $30.48 and remain below the 52-week high of $32.83, leaving the upgraded rating and upcoming operating results as potential catalysts for further movement.

About JAN

JanOne Inc is a technology and life sciences company focused on addressing the global opioid crisis. The company’s activities include developing and supporting pharmaceutical and other solutions intended to help reduce opioid-related deaths and dependency.

JanOne has also pursued blockchain and financial technology initiatives through its Alt 5 Sigma operations. These activities have included blockchain-based payment, digital asset and financial services solutions designed to help businesses manage transactions and related digital assets.

The company serves markets through its healthcare, technology and financial services initiatives, with an emphasis on solutions that can be applied internationally.